Treatment of chronic lymphocytic leukemia

descriptionPublicationkeyboard_double_arrow_right Article 01 Apr 2004 English Publisher:Elsevier BVJournal:Seminars in Oncology, volume 31, pages 60-65 (issn: 0093-7754,

Copyright policy )

Authors: Alessandra, Ferrajoli; Susan M, O'Brien;

doi: 10.1053/j.seminoncol.2004.02.017

pmid: 15124136

Treatment of chronic lymphocytic leukemia

- Summary
- Subjects
- Metrics

Abstract

Treatment options for patients with chronic lymphocytic leukemia have changed over the past two decades. This article reviews the experience accumulated with the use of alkylating agents alone and in combination; purine analogues alone and in combination and monoclonal antibodies such as rituximab, and alemtuzumab alone and in combination. The results obtained with different treatment strategies are summarized, compared, and reviewed.

Related Organizations

The University of Texas MD Anderson Cancer Center
United States

Keywords

Clinical Trials as Topic, Antibodies, Neoplasm, Antibodies, Monoclonal, Antineoplastic Agents, Antibodies, Monoclonal, Humanized, Leukemia, Lymphocytic, Chronic, B-Cell, Antibodies, Monoclonal, Murine-Derived, Humans, Enzyme Inhibitors, Rituximab, Alemtuzumab, Antineoplastic Agents, Alkylating, Vidarabine

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	12
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%